Lei Ming, Cheng Qingshu, Zhao Yachao, Liu Tao, Wang Xuejiao, Deng Yingchun, Yang Jing, Zhang Zhipei
Department of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an 710038, China.
Zhongguo Fei Ai Za Zhi. 2012 Jan;15(1):17-20. doi: 10.3779/j.issn.1009-3419.2012.01.04.
It has been proven that multidrug resistance (MDR) is the main cause of chemotherapy failure in lung cancer. Research on emergence mechanisms of MDR has great clinical significance in improving the curative efficiency of lung cancer chemotherapy. Proteins encoded by the SLC22A18 gene, which is similar to the transmembrane transporter, may influence the sensitivity of chemotherapeutics as well as the metabolism and growth of cells. In addition, these proteins probably have some effect on the development of lung cancer MDR. The aim of the present study is to investigate the expression of SLC22A18 protein in non-small cell lung cancer (NSCLC) as well as in corresponding normal lung tissue. Furthermore, the relationship between SLC22A18 expression and pathological grade and TNM stage is analyzed.
The expression of SLC22A18 was detected by EnVinsion in 96 cases with NSCLC and in corresponding normal lung tissue. Statistical analysis was performed using SPSS 17.0 statistical software.
SLC22A18 was mainly located in cell membrane and cytoplasm. The expression level of SLC22A18 in NSCLC was significantly higher than that in normal tissue (P<0.01). The positive rates in squamous cell lung cancer and lung adenocarcinoma were 68% and 78.2%, respectively (P<0.05). Moreover, the higher expression of SLC22A18 was associated with lower histological grade and later TNM stage (P<0.05).
SLC22A18 protein is overexpressed in NSCLC, and its expression is correlated with pathological grade and TNM stage. These findings provide the experimental basis for investigating the role of tumor and chemoresistance.
已证实多药耐药（MDR）是肺癌化疗失败的主要原因。研究MDR的产生机制对提高肺癌化疗疗效具有重要临床意义。SLC22A18基因编码的蛋白质与跨膜转运体相似，可能影响化疗药物的敏感性以及细胞的代谢和生长。此外，这些蛋白质可能对肺癌MDR的发生发展有一定作用。本研究旨在探讨SLC22A18蛋白在非小细胞肺癌（NSCLC）及相应正常肺组织中的表达情况。此外，分析SLC22A18表达与病理分级和TNM分期的关系。
采用EnVinsion法检测96例NSCLC患者及相应正常肺组织中SLC22A18的表达。使用SPSS 17.0统计软件进行统计分析。
SLC22A18主要位于细胞膜和细胞质中。NSCLC中SLC22A18的表达水平显著高于正常组织（P<0.01）。肺鳞癌和肺腺癌的阳性率分别为68%和78.2%（P<0.05）。此外，SLC22A18的高表达与较低的组织学分级和较晚的TNM分期相关（P<0.05）。
SLC22A18蛋白在NSCLC中过表达，其表达与病理分级和TNM分期相关。这些发现为研究肿瘤及化疗耐药的作用提供了实验依据。
